Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rimegepant + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Xiuchao Wang
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, administered alongside the standard-of-care chemotherapy regimen of nab-paclitaxel and gemcitabine (AG). Rimegepant is traditionally used for the treatment of migraine, but in this oncology context, it is being investigated for its potential to modulate the tumor microenvironment or neurogenic inflammation in pancreatic cancer. Nab-paclitaxel is an albumin-bound formulation of paclitaxel that inhibits microtubule dynamics, while gemcitabine is a nucleoside analog that interferes with DNA synthesis. The combination is currently being evaluated in a Phase Ib/II clinical trial led by Xiuchao Wang as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
- Other names
- Rimegepant plus AG chemotherapy
02
Targets
TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)Calcitonin gene-related peptide type 1 receptorDNA
Beyond the preview
Go deeper on rimegepant + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rimegepant + nab-paclitaxel + gemcitabine.